Do analysts prefer TCRT or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, TCRT or QNTM?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is TCRT or QNTM more profitable?

Alaunos Therapeutics' return on equity of -165.94% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Quantum Biopharma N/A -941.54% -224.41%

Do analysts rate XLO or QNTM?

Xilio Therapeutics currently has a consensus price target of $28.00, suggesting a potential upside of 210.77%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Xilio Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer IMMP or QNTM?

Prima BioMed presently has a consensus price target of $5.50, indicating a potential upside of 1,318.26%. Given Prima BioMed's stronger consensus rating and higher possible upside, equities analysts clearly believe Prima BioMed is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, IMMP or QNTM?

Quantum Biopharma has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.54 -$39.78M N/A N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is IMMP or QNTM more profitable?

Prima BioMed's return on equity of 0.00% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Quantum Biopharma N/A -941.54% -224.41%

Does the media prefer IMMP or QNTM?

In the previous week, Prima BioMed had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 7 mentions for Prima BioMed and 3 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.42 beat Prima BioMed's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MCRB or QNTM?

Seres Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 149.08%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Seres Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MCRB or QNTM more profitable?

Seres Therapeutics' return on equity of -130.29% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Quantum Biopharma N/A -941.54% -224.41%

Do analysts prefer TIL or QNTM?

Instil Bio currently has a consensus target price of $66.00, suggesting a potential upside of 763.87%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Instil Bio is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, TIL or QNTM?

Instil Bio is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is TIL or QNTM more profitable?

Instil Bio's return on equity of -39.76% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Quantum Biopharma N/A -941.54% -224.41%

Quantum Biopharma (QNTM) Competitors

$3.91 +0.06 (+1.56%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$4.00 +0.09 (+2.40%)

As of 06/24/2026 07:59 PM Eastern

Compare

QNTM vs. TCRT, XLO, IMMP, MCRB, and TIL

Should you buy Quantum Biopharma stock or one of its competitors? MarketBeat compares Quantum Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quantum Biopharma include Alaunos Therapeutics (TCRT), Xilio Therapeutics (XLO), Prima BioMed (IMMP), Seres Therapeutics (MCRB), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry.

How does Quantum Biopharma compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Alaunos Therapeutics has a beta of -1.07, meaning that its share price is 207% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Alaunos Therapeutics' return on equity of -165.94% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Quantum Biopharma	N/A	-941.54%	-224.41%

In the previous week, Quantum Biopharma had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Alaunos Therapeutics. Quantum Biopharma's average media sentiment score of 0.42 beat Alaunos Therapeutics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
Quantum Biopharma	Neutral

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Summary

Alaunos Therapeutics beats Quantum Biopharma on 6 of the 10 factors compared between the two stocks.

How does Quantum Biopharma compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Quantum Biopharma has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-58.52%	-151.42%	-27.61%
Quantum Biopharma	N/A	-941.54%	-224.41%

In the previous week, Quantum Biopharma had 3 more articles in the media than Xilio Therapeutics. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Xilio Therapeutics. Quantum Biopharma's average media sentiment score of 0.42 beat Xilio Therapeutics' score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Xilio Therapeutics	Neutral
Quantum Biopharma	Neutral

Quantum Biopharma has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$3.55	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Xilio Therapeutics currently has a consensus price target of $28.00, suggesting a potential upside of 210.77%. Given Xilio Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Xilio Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Xilio Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Summary

Xilio Therapeutics beats Quantum Biopharma on 8 of the 15 factors compared between the two stocks.

How does Quantum Biopharma compare to Prima BioMed?

Prima BioMed (NASDAQ:IMMP) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

In the previous week, Prima BioMed had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 7 mentions for Prima BioMed and 3 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.42 beat Prima BioMed's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Quantum Biopharma has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.54	-$39.78M	N/A	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Prima BioMed presently has a consensus price target of $5.50, indicating a potential upside of 1,318.26%. Given Prima BioMed's stronger consensus rating and higher possible upside, equities analysts clearly believe Prima BioMed is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Prima BioMed has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

Prima BioMed's return on equity of 0.00% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Quantum Biopharma	N/A	-941.54%	-224.41%

Summary

Prima BioMed beats Quantum Biopharma on 9 of the 12 factors compared between the two stocks.

How does Quantum Biopharma compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Seres Therapeutics has higher revenue and earnings than Quantum Biopharma. Seres Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	83.63	$5.70M	-$5.17	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Seres Therapeutics' return on equity of -130.29% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Quantum Biopharma	N/A	-941.54%	-224.41%

Seres Therapeutics has a beta of 0.13, meaning that its share price is 87% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

In the previous week, Seres Therapeutics had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 7 mentions for Seres Therapeutics and 3 mentions for Quantum Biopharma. Seres Therapeutics' average media sentiment score of 1.13 beat Quantum Biopharma's score of 0.42 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Seres Therapeutics	Positive
Quantum Biopharma	Neutral

Seres Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 149.08%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Seres Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Seres Therapeutics beats Quantum Biopharma on 11 of the 14 factors compared between the two stocks.

How does Quantum Biopharma compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Instil Bio has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

In the previous week, Quantum Biopharma had 3 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Quantum Biopharma and 0 mentions for Instil Bio. Quantum Biopharma's average media sentiment score of 0.42 beat Instil Bio's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Instil Bio	Neutral
Quantum Biopharma	Neutral

Instil Bio's return on equity of -39.76% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Quantum Biopharma	N/A	-941.54%	-224.41%

Instil Bio is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Instil Bio currently has a consensus target price of $66.00, suggesting a potential upside of 763.87%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Instil Bio is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 47.0% of Instil Bio shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Instil Bio beats Quantum Biopharma on 8 of the 12 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNTM vs. The Competition

Export

Metric	Quantum Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.69M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.47	20.50	25.37	23.95
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	2.92	8.26	10.76	6.41
Net Income	-$26.17M	$23.91M	$3.56B	$337.14M
7 Day Performance	2.89%	2.12%	0.99%	-1.06%
1 Month Performance	-57.68%	2.40%	0.79%	0.49%
1 Year Performance	-83.96%	57.09%	30.25%	28.43%

Quantum Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNTM Quantum Biopharma	0.2531 of 5 stars	$3.91 +1.6%	N/A	-85.6%	$14.69M	N/A	N/A	N/A
TCRT Alaunos Therapeutics	0.2413 of 5 stars	$2.24 -1.8%	N/A	-56.2%	$55.68M	N/A	N/A	40	Gap Up
XLO Xilio Therapeutics	2.0964 of 5 stars	$8.25 -1.1%	$28.00 +239.4%	-2.5%	$54.84M	$43.77M	N/A	70
IMMP Prima BioMed	1.8617 of 5 stars	$0.36 -3.8%	$5.50 +1,444.1%	-75.8%	$54.57M	$4.08M	N/A	2,021
MCRB Seres Therapeutics	2.761 of 5 stars	$5.97 +6.2%	$22.00 +268.5%	-18.9%	$54.42M	$1.15M	N/A	330	Positive News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNTM) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum Biopharma (QNTM) Competitors

QNTM vs. TCRT, XLO, IMMP, MCRB, and TIL

How does Quantum Biopharma compare to Alaunos Therapeutics?

Summary

How does Quantum Biopharma compare to Xilio Therapeutics?

Summary

How does Quantum Biopharma compare to Prima BioMed?

Summary

How does Quantum Biopharma compare to Seres Therapeutics?

Summary

How does Quantum Biopharma compare to Instil Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum Biopharma (QNTM) Competitors

QNTM vs. TCRT, XLO, IMMP, MCRB, and TIL

How does Quantum Biopharma compare to Alaunos Therapeutics?

Do institutionals & insiders believe in TCRT or QNTM?

Do analysts prefer TCRT or QNTM?

Which has more volatility and risk, TCRT or QNTM?

Is TCRT or QNTM more profitable?

Does the media favor TCRT or QNTM?

Which has better earnings & valuation, TCRT or QNTM?

Summary

How does Quantum Biopharma compare to Xilio Therapeutics?

Do institutionals & insiders hold more shares of XLO or QNTM?

Is XLO or QNTM more profitable?

Does the media refer more to XLO or QNTM?

Which has preferable valuation & earnings, XLO or QNTM?

Do analysts rate XLO or QNTM?

Which has more risk and volatility, XLO or QNTM?

Summary

How does Quantum Biopharma compare to Prima BioMed?

Does the media prefer IMMP or QNTM?

Do insiders & institutionals have more ownership in IMMP or QNTM?

Which has stronger earnings and valuation, IMMP or QNTM?

Do analysts prefer IMMP or QNTM?

Which has more volatility & risk, IMMP or QNTM?

Is IMMP or QNTM more profitable?

Summary

How does Quantum Biopharma compare to Seres Therapeutics?

Which has preferable earnings & valuation, MCRB or QNTM?

Do institutionals & insiders have more ownership in MCRB or QNTM?

Is MCRB or QNTM more profitable?

Which has more risk & volatility, MCRB or QNTM?

Does the media favor MCRB or QNTM?

Do analysts prefer MCRB or QNTM?

Summary

How does Quantum Biopharma compare to Instil Bio?

Which has more risk and volatility, TIL or QNTM?

Does the media favor TIL or QNTM?

Is TIL or QNTM more profitable?

Which has stronger earnings & valuation, TIL or QNTM?

Do analysts prefer TIL or QNTM?

Do insiders and institutionals believe in TIL or QNTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools